[Frequent ventricular tachycardias: antiarrhythmic drug treatment or catheter ablation?]

Hildegard Tanner1, Gerhard Hindricks, Hans Kottkamp

  • 1Kardiologie - Abteilung für Rhythmologie/Elektrophysiologie, Universitat Leipzig-Herzzentrum.

Herz
|December 8, 2005
PubMed

Insights

Antiarrhythmic drugs and catheter ablation are treatment options for patients with implantable cardioverter-defibrillators (ICDs) to manage ventricular arrhythmias (VTs). Treatment choice depends on individual patient factors, balancing efficacy with potential adverse effects.

Area of Science:

  • Electrophysiology
  • Cardiology
  • Pharmacology

Context:

  • Over 50% of patients with implantable cardioverter-defibrillators (ICDs) use antiarrhythmic drugs.
  • These drugs aim to reduce ventricular tachycardias (VTs) and ventricular fibrillation (VF) episodes, decreasing ICD therapies and shocks.
  • Potential benefits include improved quality of life and extended ICD battery life.

Purpose:

  • To evaluate the role of antiarrhythmic drugs and catheter ablation in managing ventricular arrhythmias in ICD patients.
  • To discuss the efficacy and adverse effects of antiarrhythmic drugs like amiodarone, sotalol, and azimilide.
  • To explore catheter ablation as an alternative or adjunctive therapy for refractory VTs.

Summary:

  • Antiarrhythmic drugs can reduce ICD shocks and improve VT cycle length, but may increase defibrillation thresholds or cause detection failure.
  • Trials show amiodarone, sotalol, and azimilide reduce ICD shocks in structural heart disease patients.
  • Catheter ablation is considered when drugs are ineffective or cause side effects, particularly for unstable VTs.

Impact:

  • Individualized treatment selection is crucial, considering patient-specific clinical and electrophysiological features.
  • VT ablation is increasingly effective but often serves as adjunctive therapy due to recurrence and new VT development.
  • Further research may clarify the optimal role of ablation as a primary treatment.

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...